CARsgen Therapeutics Holdings Limited reported no changes to its share capital for June 2026, maintaining stable equity metrics across authorised, issued and treasury shares.
Authorised and Issued Capital • Authorised share capital stayed at 200 billion ordinary shares with a par value of USD 0.00000025 per share, representing total authorised capital of USD 50,000. • Issued share count remained unchanged at 602.49 million shares, of which 594.68 million are in circulation and 7.82 million are held in treasury—approximately 1.30 % of total issued shares. • The company confirmed compliance with the Hong Kong Stock Exchange’s 25 % minimum public-float requirement.
Equity Incentive Plans • Post-IPO Share Option Scheme: 17.81 million options were outstanding at end-May; 133,500 lapsed in June, leaving 17.68 million options outstanding. No options were exercised and no shares were issued during the month. • Capacity for future grants under the Post-IPO scheme totals 23.51 million shares. • 2019 Equity Incentive Plan: a further 2.18 million shares remain available for issuance. • The Post-IPO Restricted Share Unit Scheme has no remaining shares available for grant.
Share Repurchase Status • A prior repurchase of 455,000 shares executed in October 2025 remains pending cancellation; no repurchases, cancellations, or treasury share transfers occurred in June 2026.
Capital Movements and Funding • There were zero new shares issued, zero treasury-share transfers, and no proceeds raised from option exercises during the month.
Regulatory Compliance • The issuer affirmed that all transactions were duly authorised and complied with Hong Kong Listing Rules and other applicable regulations.
Comments